Evidence map›Paper›PMID 35148313›Full record

SynthesisPLoS neglected tropical diseases2022

The changing epidemiology of human monkeypox-A potential threat? A systematic review.

Eveline M Bunge, Bernard Hoet, Liddy Chen, Florian Lienert, Heinz Weidenthaler, Lorraine R Baer, Robert Steffen

4 registry-linked trialsOpen access · goldAbstract readHistorical ArticleMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 904 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
904citing papers in PubMed, 13 pooled it
135.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06156566 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

European Randomised Clinical Trial on mPOX Infection

TypeinterventionalSponsorMiquel EkkelenkampRan2024 to 2026Enrolled150ConditionsMonkeypoxArmsTecovirimat Oral Capsule, Placebo
NCT06223919 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia

TypeinterventionalSponsorUniversidad Nacional de ColombiaRan2023 to 2025Enrolled8,686ConditionsMonkeypoxArmsLC16m8
NCT06844487 phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

TypeinterventionalSponsorJean-Pierre Van geertruydenRan2025 to 2027Enrolled344ConditionsMpox (Monkeypox), Vaccination, Immunogenicity, SafetyArmsMVA-BN standard regimen, MVA-BN half-dose regimen
NCT06844500 phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

TypeinterventionalSponsorJean-Pierre Van geertruydenRan2025 to 2027Enrolled359ConditionsNeonate, Maternal Transmission, Mpox, VaccinationArmsMVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)
3 · Its place in the literature

Who cites it

904 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,875 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Monkeypox in South Asia: a systematic review.Emerging microbes & infections · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

844 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Eveline M BungePallas Health Research and Consultancy, Rotterdam, The Netherlands.ORCID 0000-0001-7988-909X
Bernard HoetBavarian Nordic AG, Zug, Switzerland.ORCID 0000-0002-5345-3236
Liddy ChenBavarian Nordic, Inc., Morrisville, North Carolina, United States of America.
Florian LienertBavarian Nordic AG, Zug, Switzerland.ORCID 0000-0002-9161-7107
Heinz WeidenthalerBavarian Nordic GmbH, Martinsried, Germany.ORCID 0000-0002-6866-4028
Lorraine R BaerBaer PharMed Consulting, Ltd., Skokie, Illinois, United States of America.
Robert SteffenEpidemiology, Biostatistics and Prevention Institute, WHO Collaborating Center on Travelers' Health, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7917-1141
Bavarian Nordic (Germany) · DEBavarian Nordic (United States) · USUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the Democratic Republic of the Congo (DRC), it has spread to other regions of Africa (primarily West and Central), and cases outside Africa have emerged in recent years. We conducted a systematic review of peer-reviewed and grey literature on how monkeypox epidemiology has evolved, with particular emphasis on the number of confirmed, probable, and/or possible cases, age at presentation, mortality, and geographical spread. The review is registered with PROSPERO (CRD42020208269). We identified 48 peer-reviewed articles and 18 grey literature sources for data extraction. The number of human monkeypox cases has been on the rise since the 1970s, with the most dramatic increases occurring in the DRC. The median age at presentation has increased from 4 (1970s) to 21 years (2010-2019). There was an overall case fatality rate of 8.7%, with a significant difference between clades-Central African 10.6% (95% CI: 8.4%- 13.3%) vs. West African 3.6% (95% CI: 1.7%- 6.8%). Since 2003, import- and travel-related spread outside of Africa has occasionally resulted in outbreaks. Interactions/activities with infected animals or individuals are risk behaviors associated with acquiring monkeypox. Our review shows an escalation of monkeypox cases, especially in the highly endemic DRC, a spread to other countries, and a growing median age from young children to young adults. These findings may be related to the cessation of smallpox vaccination, which provided some cross-protection against monkeypox, leading to increased human-to-human transmission. The appearance of outbreaks beyond Africa highlights the global relevance of the disease. Increased surveillance and detection of monkeypox cases are essential tools for understanding the continuously changing epidemiology of this resurging disease.

Indexed as

AdolescentAdultChildChild, PreschoolDemocratic Republic of the CongoFemaleHistory, 20th CenturyHistory, 21st CenturyHumansMaleMonkeypox virusMpox, MonkeypoxTravel-Related IllnessYoung Adult

Identifiers

PMID35148313
PMCPMC8870502
OpenAlexW4211060053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.